Sign inJoin waitlistJoin the waitlist

Diwakar Davar

Associate Division Chief for Academic Affairs · UPMC Medical Education

Credentials: · · · · · ·

History

UPMC Medical Education
Present
UPMC Medical Education
Present
Cancer Immunology and Immunotherapy Program · UPMC Medical Education
Present

Medical Oncology
UPMC Medical Education
2009–2012
Internal Medicine
2005–2008
Doctor of Medicine
2001–2005

Research

Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients
Science · 2021 · Co-first of 32 authors · 1,389 citations
Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
Cell · 2023 · 616 citations
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
Systematic review or meta-analysis · Nature Medicine · 2022 · Co-first of 31 authors · 411 citations

John Kirkwood
40 papers
HZ
Hassane Zarour
25 papers
JL
Jason Luke
20 papers
YN
Yana Najjar
20 papers
Arivarasan Karunamurthy
9 papers
AT
Ahmad Tarhini
8 papers
Antoni Ribas
5 papers
DF
Dylan Fortman
5 papers · 5 as a resident
JR
John Rhee
5 papers
Liza Villaruz
5 papers
Richelle DeBlasio
5 papers
AL
Aofei Li
4 papers · 4 as a fellow

Grants

Proteogenomic Studies to Understand Mechanisms and Drivers of Resistance to Immunotherapies
National Cancer Institute · U01
PI · $5.6M · Fred Hutchinson Cancer Center
2022–2027
Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma
National Cancer Institute · R01
PI · $2.6M · University of Pittsburgh at Pittsburgh
2021–2027

Clinical trials

Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)
Principal investigator · Withdrawn · Phase 2
Diwakar Davar
2027–2031
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Principal investigator · Recruiting · Phase 2
Diwakar Davar
2025–2030
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Principal investigator · Recruiting · Phase 2
Diwakar Davar
2025–2030
Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma
Principal investigator · Withdrawn · Phase 2
Diwakar Davar
2025–2029